esophageal or gastroesophageal junction cancer esophageal cancer
Conditions
Interventions
n.a.
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Inclusion criteria
Inclusion criteria: All patients with a confirmed diagnosis of esophageal or gastroesophageal junction cancer who completed esophageal or gastroesophageal resection and received at least one cycle of adjuvant nivolumab at Erasmus MC, Amsterdam UMC or UMCG between January 1st, 2022 and December 31st, 2023 will be included
Exclusion criteria
Exclusion criteria: Fully treated at another center, incomplete data as a result of partial treatment at another center, registered with objection to use data for studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is the incidence of grade III-V adverse events according to CTCAE v5.0. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes measures are related to the safety and tolerability of treatment, such as individual adverse events, and their management, as well as the impact of treatment on disease recurrence and survival. | — |
Countries
Netherlands
Contacts
Public ContactJ.J. de Haan
Universitair Medisch Centrum Groningen
Outcome results
None listed